Washington, DC (September 14, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that two companies – Ipsen Biopharmaceuticals and Onyx Pharmaceuticals – have joined the association as new research associate members. PhRMA’s Board of Directors recently approved the membership expansion.
“We are thrilled to welcome Ipsen Biopharmaceuticals and Onyx Pharmaceuticals to our membership. These two emerging companies are at the forefront of some of the most exciting biopharmaceutical research taking place in the industry today,” said PhRMA Executive Vice President for Advocacy Chip Davis. “We look forward to working with the leadership of these companies as we advocate for patient-centered policies that will help ensure that America’s status as the world leader in medical innovation continues for decades to come.”
Ipsen Biopharmaceuticals is the U.S. affiliate of Ipsen Group, a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen Biopharmaceuticals, with U.S. headquarters in Basking Ridge, NJ, is focused on developing specialty healthcare solutions for targeted debilitating diseases. Ipsen Group specializes in therapies in the areas of neurology, endocrinology, uro-oncology, and hemophilia. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The company’s R&D approach is targeted on innovative and differentiated technological patient driven platforms, peptides and toxins. Ipsen has total worldwide staff of nearly 4,500 employees.
Commenting on the announcement, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, said: “I have the great pleasure to announce that our Group is joining PhRMA. We are looking forward to working with other PhRMA members towards improved frameworks that will enable patients’ timely access to the treatment and care they need.”
Onyx Pharmaceuticals, Inc., based in South San Francisco, CA, is a global biopharmaceutical company engaged in the development and commercialization of cancer therapies. The company has approved medicines to treat patients with solid and hematologic cancers, and a pipeline of anticancer compounds at various stages of clinical development. Onyx has a growing staff of more than 650 employees in the U.S. and Europe.
“Onyx is pleased to join the other PhRMA research associate member companies in the important mission of advancing medical innovation by bringing safe and effective treatments to patients and ensuring access to high-quality therapies,” said John E. Osborn, Senior Vice President of Global Corporate Affairs for Onyx Pharmaceuticals. “PhRMA plays an important role in advocating policies that make healthcare breakthroughs possible, and Onyx looks forward to being a part of the dialogue.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.
Find PhRMA Online:
- Website – http://www.phrma.org
- facebook – www.facebook.com/PhRMA
- Blog – www.phrma.org/catalyst
- Twitter – www.Twitter.com/PhRMA and www.Twitter.com/PhRMApress
- YouTube – www.youtube.com/PhRMApress
For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org